ALEXANDRIA, Va., July 9 -- United States Patent no. 12,351,561, issued on July 8, was assigned to Theravance Biopharma R&D IP LLC (South San Francisco, Calif.).
"Crystalline (2S,4R)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof" was invented by Adam D. Hughes (Half Moon Bay, Calif.), Melissa Fleury (Brisbane, Calif.), Miroslav Rapta (San Carlos, Calif.), Venkat R. Thalladi (Foster City, Calif.), R. Michael Baldwin (San Mateo, Calif.) and David L. Bourdet (Millbrae, Calif.).
According to the abstract* released by the U.S. Patent & Trademark Office: "In one aspect, the invention relates to a crystalline form of the structure:or a pharmaceutically acc...